WILDER FULFORD PhD

MANAGING DIRECTOR
M&A / CORPORATE FINANCE / HEALTHCARE & LIFE SCIENCES / INDUSTRIALS & BASIC MATERIALS
LONDON / EUROPE / GLOBAL

Wilder is a Managing Director at KingsRock Advisors in London. He has more than 30 years of experience advising boards, management teams, entrepreneurs, private equity firms and investors on M&A, corporate finance, private capital and strategic transactions across Europe, the US and Asia.

Wilder began his career at James D. Wolfensohn in New York, first in venture capital and then as a multi-industry M&A banker. He later joined Salomon Brothers, subsequently Salomon Smith Barney/Citigroup, where he became a Partner/Managing Director and advised on large-cap, cross-border and complex transactions, including hostile M&A, defence assignments, restructurings and carve-outs across a wide range of industries, with a concentration in Healthcare.

At Merrill Lynch in London, Wilder was Head of European M&A for Healthcare, Chemicals and Basic Industries, with coverage across healthcare, chemicals, metals and mining, paper and forest products and basic materials. He also chaired the European Fairness Opinion Committee and served on the global Managing Director Promotion Committee.

Wilder has repeatedly built and led advisory platforms. He built Bank of America’s European healthcare investment banking team, ran European Healthcare M&A and co-led European healthcare coverage at Deutsche Bank, and founded Torreya Partners’ European office. At Deutsche Bank, his work also included financial sponsor coverage, leveraged finance and acquisition financing as well as strategic M&A.

In 2015, Wilder founded The Fulford Group, an independent advisory firm providing M&A, corporate finance and strategic advice to healthcare and life sciences companies globally. Over his career he has advised on close to 100 M&A, financing and strategic transactions, with an aggregate value in excess of $100 billion.

Wilder is also an Operating Partner and member of the Investment Committee of Quadria Capital, a specialist Asian healthcare private equity firm.  He holds a PhD in Molecular Biology from The Rockefeller University and a BSc in Biochemistry from the University of Toronto.